ISSN: 0392-856X
Journal Home
Journal Guideline
Clinical and Experimental Rheumatology Q2 Unclaimed
Clinical and Experimental Rheumatology is a journal indexed in SJR in Immunology and Immunology and Allergy with an H index of 108. It has an SJR impact factor of 0,907 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,907.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
0,907
SJR Impact factor108
H Index357
Total Docs (Last Year)1137
Total Docs (3 years)10284
Total Refs2925
Total Cites (3 years)901
Citable Docs (3 years)2.63
Cites/Doc (2 years)28.81
Ref/DocOther journals with similar parameters
Clinical and Experimental Allergy Q2
Expert Review of Clinical Immunology Q2
Immunology and Cell Biology Q2
International Reviews of Immunology Q2
Clinical and Experimental Immunology Q2
Compare this journals
Aims and Scope
Best articles by citations
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
COVID-19: the new challenge for rheumatologists
One year in review 2022: systemic lupus erythematosus
JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis
Fibromyalgia in women: somatisation or stress-evoked, sex-dimorphic neuropathic pain?
Skeletal muscles and Covid-19: a systematic review of rhabdomyolysis and myositis in SARS-CoV-2 infection
Defining anti-synthetase syndrome: a systematic literature review
Fibromyalgia position paper
Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis
Pathogenesis of rheumatoid arthritis: one year in review 2022
One year in review 2020: novelties in the treatment of rheumatoid arthritis
The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature
The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome
One year in review 2021: fibromyalgia
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management
Physical and mental impact of COVID-19 outbreak on fibromyalgia patients
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study
Juvenile dermatomyositis. Where are we now?
One year in review 2021: pathogenesis of rheumatoid arthritis
Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis
Treatment of relapsing polychondritis: a systematic review
Pain and transition: evaluating fibromyalgia in transgender individuals
One year in review 2021: Sjögren's syndrome
SARS-CoV-2 infection in patients with systemic autoimmune diseases
Comments